The faculty for this activity are listed below:

G. Travis Clifton, MD (Moderator)
Brooke Army Medical Center

Mihir M. Shah, MD (Panelist)
Emory University / Winship Cancer Institute

Salma Jabbour, MD (Panelist)
Rutgers Cancer Institute of New Jersey

Howard Hochster, MD (Panelist)
Rutgers Cancer Institute of New Jersey

Onkar Khullar, MD, MSc (Panelist)
Emory University / Winship Cancer Institute

"As of May 27, 2022, the FDA has approved nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 status."

At the conclusion of this activity, participants should be able to:

• Describe the mechanistic rationale for the role of immunotherapies in earlier stage gastric and esophageal cancer
• Summarize available and ongoing clinical trial data on the use of immune checkpoint inhibitors as adjuvant or neoadjuvant therapy in resectable gastric and esophageal cancers
• Translate the latest clinical trial data to identify appropriate patients with significant recurrence risk who may benefit from approved or emerging uses of neoadjuvant or adjuvant immunotherapy
• Assess emerging biomarkers for ICIs in the early disease setting and their potential predictive role in assessing long term benefits

The estimated time to complete this entire activity is 1 hour.

Release Date

           December 22, 2021

CME Expiration Date

           December 22, 2022

As required by the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all planners, reviewers, presenters, instructors, moderators, authors, and other individuals in a position to control or influence the content of an activity must disclose ALL financial relationships with any ineligible company that have occurred within the past 24 months. Ineligible companies are those that cannot be accredited in the ACCME System and whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

As the accredited provider, SSO is responsible for identifying relevant financial relationships between individuals in control of educational content and ineligible companies and managing these to ensure they do not introduce commercial bias into the education. Financial relationships of any dollar amount are defined as relevant if the educational content is related to the business lines or products of the ineligible company.

All identified conflicts of interest must be resolved, and the educational content vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations.  If you perceive bias while participating in this activity, please advise us of the circumstances when completing your postactivity evaluation form.

All identified conflicts of interests have been resolved.

Faculty

G. Travis Clifton, MD has disclosed the following financial relationships: Parthenon Therapeutics - Employee, Stocks

Mihir Shah, MD, MSc, has disclosed no financial relationships.

Salma Jabbour, MD has disclosed the following financial relationship:Merck & Co. - Consultant, Contracted Research; IMX Medical - Consultant; Syntactx - Consultant; ASTRO - Speaker

Onkar Khullar, MD has disclosed no financial relationships

Howard Hochster, MD has disclosed the following financial relationship: Bayer - Consultant; Genentech - Consultant; Merck - Consultant; TRIGR - Consultant, Stocks; Processa - Consultant; Natera - Speaker

Planners, Reviewers, and Staff

Timothy Fitzgerald, MD, CME Committee Reviewer, has disclosed no financial relationships.

Ibrahim Sallam, MD, CME Committee Reviewer, has disclosed no financial relationships.

Krystine Hansen, CAE and Kelley Gazer, Society of Surgical Oncology, have disclosed no financial relationships.

Michelle Forcier, Natasha Mitchner, Lisa Keckich, Sara Brykalski, Nicolle Rochino, Vanessa Senatore, Amanda Kaczerski, Katlyn Cooper, Emily Eennett and Ritesh Kothari, Academy for Continued Healthcare Learning, have disclosed no financial relationships.

Patti Stella, CAE, CHCP, Director of Education, Society of Surgical Oncology, has disclosed the following financial relationships: Horizon Pharmaceutical PLC – Stocks; SPDR Biotech – Stocks.

This educational activity may include discussions of unlabeled/unapproved uses of drugs or devices. Participants are advised to refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Opinions expressed in this educational activity are those of the expert contributors and do not necessarily represent the views of the Society of Surgical Oncology or any other organization associated with this activity.